Genetic variation in the catechol-O-methyltransferase (COMT) gene may influence the susceptibility to schizophrenia and the response to neuroleptic treatment. The authors tested for an association between a COMT haplotype and schizophrenia-spectrum disorders and for an eventual influence of a specific COMT genotype in the clinical outcome and in the response to treatment. The genotypes for single nucleotide polymorphisms rs737865, rs4633, rs6267, rs4680 (Val 158 Met) and rs165599 were determined in 207 patients with schizophrenia-spectrum disorders and 204 paired controls. Statistical tests for linkage disequilibrium and for case-control differences in haplotype frequencies were performed using log-linear modelling embedded within the expectation-maximization algorithm. P-values based on permutations were calculated using the software UNPHASED, and odds ratios were estimated using the SHEsis platform. The response to neuroleptic treatment was assessed by the Global Assessment of Functioning scale and the severity of psychotic symptoms by the positive and negative syndrome scale (PANSS) scale. The overall disease status was significantly associated with the T-G (Val) diplotype for rs4633-rs4680 (P ¼ 0.0049). A significant association was observed between schizophrenia, but not other related disorders, and genotypes GG (Val/Val) for rs4680 and TT for rs4633. Val/Val patients with schizophrenia showed a higher severity of the psychotic symptoms and a worse response to the neuroleptic treatment. COMT genetic variation seems to be involved in the psychotic symptomatology of the schizophreniaspectrum disorders and specifically in the narrow schizophrenia phenotype. Our results show an influence of the Val 158 Met polymorphism on the severity of psychotic symptoms and on the response to treatment.
Introduction
Schizophrenia is a complex illness that cannot be explained by a single genetic or environmental etiologic factor, with an important genetic component of around 80%. 1, 2 Two recent meta-analyses, 3, 4 which include wholegenome genetic studies, have concluded that the genetic regions of maximum overlap are located at 22q and 8p, and the most promising schizophrenia genes at those regions are the catechol-O-methyltransferase (COMT, 22q11.21) and neuregulin (8p21-p12) genes. The high incidence of schizophrenia among patients suffering from 22q11.2 microdeletion syndrome (velocardiofacial syndrome), additionally supports the idea that this region contains one or more genes that could contribute to the development of schizophrenia. 5 COMT catabolyzes monoamines in the brain tissue, including dopamine, and several studies have implicated dopamine in the development of some of the most characteristic symptoms of schizophrenia. 6 A functional polymorphism in exon 4 of the COMT gene (G to A) causes a substitution of valine to methionine at codon 158 (Val 158 Met) of the membrane-bound COMT (MB-COMT), the predominant isoform in the brain, resulting in a lower thermostability that causes a lower activity of the Met variant at physiologic temperature. 7, 8 Because of the genomic location of the gene and its involvement in the metabolism of dopamine in the prefrontal cortex, the COMT gene has recently been suggested as a possible genetic component in the development of schizophrenia, 9 and it has also recently been cited as the only gene for which a causal allele and a mechanism that predispose one to suffer from schizophrenia have been identified. 10 A recent meta-analysis, 11 including 18 studies on this polymorphism, detected a significant increase in the odds ratio (OR) associated with the Val allele and the risk of suffering schizophrenia. Although the increase in the OR is moderate (OR ¼ 1.1 for case-control studies, OR ¼ 2.2 for family studies), this study concludes that the Val allele can be considered a risk factor for schizophrenia. Nevertheless, two other studies did not report a significant contribution of the Val 158 Met polymorphism of the COMT gene to schizophrenia and concluded that either the Val allele is in linkage disequilibrium (LD) with a nearby causal marker or the results differ when ethnically different populations are considered or the risk conferred by the Val allele is extremely low. 12, 13 Results have also been obtained that suggest an eventual influence of this polymorphism in the response of schizophrenic patients to typical 14 and atypical 15 neuroleptics. The first studies focused on the role of the Val 158 Met polymorphism in the modulation of the prefrontal cortex function detected an association of the Val allele with a worse performance in cognitive tasks dependent on the region, 9, 16 and recent studies have obtained results that are concordant with this finding. [17] [18] [19] [20] This association, together with the fact that the Val allele has been observed to be more prevalent among schizophrenic patients than among controls, is concordant with a series of previous studies that provided evidence for such cognitive deficits in schizophrenia. 21, 22 The pathophysiological basis of the influence of COMT in the prefrontal cortex function has also been studied, with results that are in agreement with the dopaminergic hypothesis of schizophrenia. [23] [24] [25] Current data support the idea that other variants of the COMT gene could also be of relevance. 26 In fact, a casecontrol study carried out in a large sample of Ashkenazi Jews 27 found a highly statistically significant association between schizophrenia and two other polymorphisms of the COMT gene (rs165599 and rs737865), and another work 28 assessing the relevance of some haplotypes of the COMT gene in patients with schizophrenia belonging to different populations supports the hypothesis that the presence of some haplotypes can be associated with the differential expression from the P2 promoter, which directs the expression of the MB-COMT.
The aims of this work were to test for an association between a COMT haplotype and schizophrenia spectrum disorders and to search for an eventual influence of a specific genotype of the COMT gene in the clinical outcome and in the response to neuroleptic treatment.
Results
Patients and controls were comparable in gender and age (P ¼ 0.38; patients: 37.67 (15; 84) years, controls: 38.99 (18; 74) years).
Of the single nucleotide polymorphisms (SNPs) studied, rs6267 was not polymorphic in our Spanish sample and was therefore not included in further statistical analyses.
The allele frequencies of the remaining SNPs (rs737865, rs4633, rs4680 and rs165599) were tested for consistency in the whole sample and among cases and controls separately with those expected from Hardy-Weinberg equilibrium (HWE) (data not shown).
None of the SNPs were associated separately with the overall disease status. Haplotype analysis based on the expectation-maximization (EM) algorithm and likelihoodratio tests identified an association between the overall disease status and the rs4633-rs4680 (T-G) diplotype (P ¼ 0.0049), which includes the Val allele for rs4680 (or Val 158 Met) ( Table 1 ). The P-values based on the w 2 distribution indicated statistically significant LD among these markers (Po0.001 in patients and in controls, data not shown). SNPs rs4633 and rs4680 were in strong LD (D and r 2 40.9 in patients and controls; Table 1 ).
The distribution of the genotypes for SNPs rs4633 and rs4680 was not homogeneous throughout the schizophrenia spectrum (P ¼ 0.012, P ¼ 0.045, respectively), and a significant association was observed between schizophrenia and the TT genotype for SNP rs4633 and GG of rs4680 (encoding for Val/Val), which was not detected in the remaining diagnostic subgroups ( Table 2) . Nevertheless, the degree of specificity of this association is limited given the small number of patients within some diagnostic categories.
In the group of patients with schizophrenia, the analysis of the Val 158 Met genotype with regard to the severity of the psychotic symptoms, assessed by the positive and negative syndrome scale (PANSS) subscale rating scores both at baseline (i.e., at the acute worsening of psychotic symptoms) and after the 6-month period of treatment, indicated that Val/Val patients showed more severe psychotic symptomatology (and thus higher scores in all PANSS subscales) in both assessments than Met/Met and Val/Met patients (Kruskal-Wallis test) (Figure 1 (Figure 2 ). However, this difference did not fully translate in terms of PANSS scores, and the differences between scores pre-treatment and post-treatment did not reach statistical significance but indicated a tendency (all PX0.095). Thus, only a small effect of the Val 158 Met genotype was detected in the response to treatment in terms of global functioning. It is important to emphasize that this effect cannot be attributed to differences in the treatment received by patients belonging to different genotypic categories (Table 3) . 
rs737865 -rs4633-rs4680-rs165599. e Exclusively for the alleles of SNP rs737865, we have used the same forward sense nomenclature as in Shifman et al. 
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In the remaining diagnostic categories, no differences were detected between the Val 158 Met genotype groups of patients with regard to the severity of psychotic symptoms or to the response to the neuroleptic treatment.
To assess whether the risk diplotype, T-G for rs4633-rs4680, influenced the response to treatment, patients were classified as responders if a reduction of more than 30% of pretreatment PANSS score was achieved after 6 months of neuroleptic treatment, and the genotype frequencies were then estimated among responders and non-responders.
A significant association was detected between the risk haplotype and response to treatment in PANSS-T and in all PANSS subscales, which is due to male patients (this association was not detected in female patients) ( Table 4) .
As rs737865 and rs165599 have been identified to be differently associated with schizophrenia in function of the gender, 25 the frequencies of the rs737865-rs165599 diplotypes were estimated in males and females independently, and a statistically significant increase of the frequency of the A-G diplotype was observed in male patients (P ¼ 0.03), but not in male controls (Table 5) .
Discussion
This study detected an association between the schizophrenia spectrum disorders and a diplotype of the COMT gene that includes the Val allele of the Val 158 Met polymorphism, although none of the SNPs screened was independently associated with the overall disease status. This finding could explain in part the discrepancies between previous reports investigating the association of the Val allele with schizophrenia and supports a genetic model in which several genetic markers would have a small additive effect on the development of schizophrenia. Considering the association between the T-G genotype for SNPs rs4633-rs4680 and the overall disease status, and in view of the genomic location of rs4633 and rs4680 and the high LD between them, these results suggest that these SNPs might be related to the schizophrenia spectrum disorders. In spite of the amplitude of the confidence interval, we believe that the association of this diplotype with the overall disease status is strong enough (P ¼ 0.0049; OR ¼ 6.13; 95% CI 1.35-27.79) ( Table 1) Clinical implication of COMT in schizophrenia P Molero et al to suggest that functional studies focused on rs4633 (and also on the genomic region spanned between rs4633 and rs4680) could provide new evidence of the involvement of both SNPs in schizophrenia.
Evidence gathered in recent years suggests that alterations in the neurochemical mechanisms at the dorsolateral and prefrontal cortex, which are responsible for information processing, constitute a core aspect of the pathophysiology of schizophrenia, from which many of the clinical and biological features of this disorder are derived. 29 There is evidence of the influence of the COMT Val
158
Met polymorphism in the execution of cognitive tasks dependent on the prefrontal cortex, with the Val allele being associated with decreased performance in specific neuropsychological tests and in the physiological response of this cortical region measured by functional magnetic resonance imaging. 9, 26, [30] [31] [32] This association, together with the fact that the Met allele at position 158 seems to constitute an exclusively human mutation (it has not been found in the higher primates), 33 has given consistency to the theory that such mutation may have an important evolutive implication in the prefrontal human cortex. From the impact of the COMT genotype on the prefrontal information process, and given the association of schizophrenia with alterations in the prefrontal Other include amisulpride, chlorpromazine, fluphenazine, levomepromazine, perphenazine, pimozide, thioridazine, trifluoperazine, tiprasidone, zuclopenthixol. Table 4 Estimated frequencies and association significance of rs4633-rs4680 T-G diplotype in terms of PANSS score after 6 months of treatment Met genotype in terms of the differences in the GAF score (GAF score after 6 months of treatment minus GAF score at the acute worsening of the psychotic symptoms; P ¼ 0.03, Kruskal-Wallis test).
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Clinical implication of COMT in schizophrenia P Molero et al cortex, it can be inferred that such a genotype may constitute a risk factor for the development of schizophrenia. 23 The results reported herein are in agreement with those providing evidence of the association of the Val allele with schizophrenia. 9 Schizophrenia and schizoaffective disorders have been considered together in molecular genetic studies within a 'core' phenotype. 34 However, we have covered the whole schizophrenia spectrum to study the putative homogeneity of such a 'core' phenotype in terms of the COMT genotype for the SNPs selected in this work, and we have detected an association only between the narrow schizophrenia phenotype (not with schizoaffective disorder nor with the rest of the schizophrenia spectrum) and the genotypes Val/Val (rs4680) and TT (rs4633). Although the degree of specificity of this association is limited given that some diagnostic categories included only a small number of patients, it could be suggested that this finding might be an argument for considering schizophrenia and schizoaffective disorders separately in the studies of the involvement of the genetic variation of COMT in psychosis.
On the other hand, many of the studies focused on the association between the Val 158 Met polymorphism of the COMT gene and schizophrenia set inclusion criteria limited to that specific disorder to 'purify' the sample. A disadvantage of using such criteria is that the degree of specificity of the susceptibility genotype for schizophrenia remains unexplored, as does the possible influence of the genotype throughout the schizophrenia spectrum. Although it is beyond the scope of this article, it could be hypothesized that the molecular mechanisms by which the Val allele plays a role in schizophrenia could also be partially shared by the pathophysiology of the schizoaffective disorder. This thesis could be of value in the search for different biological markers in the schizophrenia spectrum and would favor maintaining the position of the schizoaffective disorder closer to the schizophrenia spectrum than to the bipolar spectrum.
Our results suggest a possible sex-specific role of COMT, also detected by other authors in schizophrenia 27 and obsessive-compulsive disorder, 35 although the conclusions in this regard are controversial. The differences detected in the effect of the Val 158 Met allele according to sex have been proposed to reflect partial sex-based distinctions in the etiology of schizophrenia, which may be related to differences in COMT activity, although more sophisticated mechanisms such as transmission rate distortion could be involved.
Concerning the influence of the Val 158 Met polymorphism in the severity of psychotic symptoms, Val/Val patients showed more intense positive and negative symptoms in the acute worsening of the psychotic symptoms both at the beginning of the study and after treatment, and therefore they obtained higher scores in the PANSS-P and PANSS-N subscales pretreatment and post-treatment than Val/Met and Met/Met patients (Figure 1a and b) . Although our results need to be replicated to further clarify whether the presence of the Val/Val genotype is a risk factor for a higher severity of positive and negative symptoms, our findings are consistent with the model that explains positive and negative symptoms as the result of a cortical-subcortical dopaminergic imbalance, which originates a state in which a subcortical mesolimbic functional hyperdopaminergia (hyperstimulation of D 2 subcortical receptors; positive symptoms) coexists with a cortical functional hipodopaminergia (hypostimulation of D 1 cortical receptors; negative symptoms and cognitive impairment), 6 given the fact that the relatively high COMT activity conferred by the Val allele not only causes low prefrontal cortex dopamine levels, but also may enhance dopamine biosynthesis in the midbrain by means of greater tyrosine hydroxylase mRNA expression. 25 An important limitation of the results of this work concerning the influence of Val 158 Met genotype in the severity of symptoms and in the response to treatment is that given its observational and naturalistic design, and the fact that more than 25% of the patients were under treatment with more than one neuroleptic during the observational period, it was not possible to investigate interactions between specific neuroleptic drugs and the Val 158 Met genotype, as has been done with olanzapine in the work by Bertolino et al. 36 However, given the limited statistical power of our study, the fact that a significant effect has been detected supports the idea that an increase of the number of patients treated homogeneously would lead to an enhancement of the differences detected herein.
Our results indicate a weak influence of the Val 158 Met polymorphism in the response to treatment, given that no statistically significant differences were detected in the PANSS scale rating score differences, and only a small effect Pearson's P-value ¼ 0.038.
Clinical implication of COMT in schizophrenia P Molero et al has been detected in terms of the differences in the GAF scale rating scores (P ¼ 0.03), with Val/Val patients showing a slightly poorer recovery after 6 months of treatment ( Figure 2 ). The possible influence of the Val 158 Met genotype of the COMT gene in the response to the neuroleptic treatment has also been studied in two recent and concordant reports, 36, 37 which detected a better outcome for Met allele carriers in terms of the performance in specific neuropsychological tests and of the PANSS-N rating subscale. However, this difference in the response to the neuroleptic treatment was not identified in the remaining PANSS subscales, which could be explained by the sample size (20 and 30 patients, respectively; 8 weeks of treatment). Our results, using the GAF and the PANSS scales, and a longer period of treatment (6 months), although showing a small effect, are in good agreement with those obtained by Bertolino et al. 36 and Weickert et al. 37 In our sample, the Val/Val genotype was associated with a higher severity of psychotic symptoms measured by the PANSS scale ( Figure 1 ) and a smaller enhancement of the global functioning after period of treatment measured by the GAF scale than Met/Met and Val/Met patients ( Figure 2) .
Interestingly, although in this work the disadvantage of the Val allele was significant in all PANSS subscales, it was only in the PANSS-N subscale in which the most clear linearlike effect of Val/Val4Val/Met4Met/Met was detected in the rating scores, both at pretreatment and after treatment assessment (Figure 1b) . Thus, the effect of Val
158
Met in the response to treatment seems to be especially clear in terms of negative symptoms. These results, together with those obtained by Bertolino et al. 36 and Weickert et al., 37 suggest that the advantage conferred by the Met allele in the response to the neuroleptic treatment is evident shortly after the administration of the neuroleptic drugs, and it seems to be still detectable after 6 months of treatment. It would be interesting to investigate this effect in larger series with longer periods of treatment to clarify the magnitude of this effect in the long-term prognosis.
In brief, our results support the hypothesis that the COMT genetic variation is involved in the severity of psychotic symptomatology of schizophrenia and might influence the response to the neuroleptic treatment.
Materials and methods

Study subjects
Patients being treated at the Department of Psychiatry of the University Clinic of Navarra with a diagnosis of any of the mental disorders from the schizophrenia spectrum according to the DSM-IV were recruited. Only chronic patients were recruited (median length of disease 10.2 years), who were clinically compensated at the time of recruitment and who provided informed consent signature. The determination of clinical compensation was done according to these criteria: (i) outpatient treatment with no need for hospitalization during the previous year and (ii) maintained Global Assessment of Functioning Scale (GAF, DSM-IV Axis V) of 60 or higher during the previous year.
The recruitment included two direct interviews, each with a different senior psychiatrist, in order to verify the diagnosis. Only patients with Caucasian ancestry were included, since ethnicity may play an important role in genetic heterogeneity at certain susceptibility loci. All patients reporting substance abuse or suffering from another illness justifying psychiatric symptomatology were excluded. After complete description of the study to the subjects, written informed consent was obtained. The ethical approval was granted by the ethics committee of the University Clinic of Navarra.
The observational period for each patient began when a change in the neuroleptic treatment was required owing to an acute worsening of the psychotic symptoms. This is a naturalistic and prospective study, in which all patients were followed by a research group of psychiatrists during an observational period of 6 months following the aforementioned acute psychotic decompensation. The severity of the psychotic symptoms was assessed in two interviews by means of the PANSS scale rating scores: one at baseline (i.e., at the acute worsening of psychotic symptoms) and the other after the 6-month period of treatment. In both interviews the global psychological, social and occupational functioning were also measured by means of the GAF scale. To achieve an acceptable degree of homogeneity in the neuroleptic treatment, only patients in whom a switching strategy was adopted were selected for the study. The same neuroleptic or neuroleptics prescribed to control the acute psychotic worsening were maintained during the observational period.
A total of 207 patients were selected belonging to the following diagnostic groups: schizophrenia n ¼ 114; schizoaffective disorder n ¼ 42; acute and transient psychotic disorder n ¼ 25; persistent delusional disorder n ¼ 14; schizotypal disorder n ¼ 11; other non-organic psychotic disorder n ¼ 1. Among them 118 were males and 89 females, the mean age of patients was 37.67 (13.91), the age at diagnosis was 25.3 (4.1), the mean length of disease was 10.2 years (2.1), and the median dose of neuroleptics used as maintenance treatment was 480.2 (151.1) chlorpromazine equivalents. The clinical parameters and the neuroleptic treatment (doses and specific neuroleptics used) did not differ substantially among COMT genotype groups.
Healthy controls without personal or family history of psychiatric disorders were also recruited (n ¼ 204). Patients and controls were comparable in age and sex.
Genotyping assays
Each patient donated a 5 ml blood sample anticoagulated in ethylene diamine tetraacetic acid, and DNA was obtained with a commercial method (Qiamp DNA Blood Mini Kit, Qiagen) (Qiagen GmbH, Hilden, Germany) following the manufacturer's instructions.
The Val 158 Met (rs4680) variant was genotyped using polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism analysis. For the remaining SNPs tested (rs6267, rs165599, rs737865 and rs4633), genomic DNA was diluted to 100 ng/ml, and the polymorphic sites were interrogated with KASPar (http:// www.kbioscience.co.uk), which is a fluorescence resonance energy transfer (FRET)-based SNP genotyping chemistry that incorporates competitive allele-specific PCR.
Statistical analysis
An anonymous database with the genotypes and the relevant clinical data was built in SPSS v11 (Statistical Package for the Social Sciences, Chicago, IL, USA).
Allele frequencies were tested for HWE after the estimation of allele and genotype frequencies by gene counting method. w 2 statistics were used to compare allele and genotype frequencies in patients versus controls.
The indexes D 0 and r 2 were calculated as a measure of LD between pairs of SNPs. Statistical tests for LD and tests for case-control differences in haplotype frequencies were performed using log-linear modelling embedded within the EM algorithm implemented in the statistical package STATA 8.2 (STATA Statistical Software 2004). The EM algorithm handles the phase uncertainty, and the log-linear modelling allows testing for LD and disease association by means of the likelihood-ratio test. 38, 39 Additionally, P-values based on permutations were calculated using the software UNPHASED, 40 and odds ratios (OR) with a 95% confidence interval were estimated using the SHEsis platform. 41 The association between the presence of a specific genotype and the psychiatric diagnosis was assessed using the w 2 test. The response to the neuroleptic treatment and the severity of symptoms, assessed as the difference in the GAF and PANSS scales, respectively, did not fulfill normality criteria, and non-parametric tests were therefore used for their analysis (Kruskal-Wallis tests).
For descriptive purposes, the parametric variables were expressed as mean (s.d.) whereas the non-parametric variables were expressed as median (interquartile range) (IQR).
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COMT catechol-O-methyltransferase EM expectation-maximization HWE Hardy-Weinberg equilibrium MB-COMT membrane-bound COMT SNP single nucleotide polymorphism
